

# Paolo Montuschi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/281811/publications.pdf>

Version: 2024-02-01

139  
papers

9,010  
citations

38660

50  
h-index

40881

93  
g-index

140  
all docs

140  
docs citations

140  
times ranked

8794  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mapping atopic dermatitis and anti-IL-22 response signatures to type 2 low severe neutrophilic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 89-101.	1.5	22
2	Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation. <i>European Respiratory Journal</i> , 2022, 59, 2100142.	3.1	10
3	A multi-omics approach to delineate sputum microbiome-associated asthma inflammatory phenotypes. <i>European Respiratory Journal</i> , 2022, 59, 2102603.	3.1	11
4	Urinary metabotype of severe asthma evidences decreased carnitine metabolism independent of oral corticosteroid treatment in the U-BIOPRED study. <i>European Respiratory Journal</i> , 2022, 59, 2101733.	3.1	13
5	Sleep Deprivation, Immune Suppression and SARS-CoV-2 Infection. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 904.	1.2	18
6	Clinical and transcriptomic features of persistent exacerbation-prone severe asthma in U-BIOPRED cohort. <i>Clinical and Translational Medicine</i> , 2022, 12, e816.	1.7	11
7	Dupilumab and tezepelumab in severe refractory asthma: new opportunities. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232210973.	1.1	6
8	Urinary Leukotriene E <sub>4</sub> and Prostaglandin D <sub>2</sub> Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type 2 Inflammation. A Clinical Observational Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 37-53.	2.5	49
9	Exploring the performance of a functionalized CNT-based sensor array for breathomics through clustering and classification algorithms: from gas sensing of selective biomarkers to discrimination of chronic obstructive pulmonary disease. <i>RSC Advances</i> , 2021, 11, 30270-30282.	1.7	12
10	Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. <i>World Allergy Organization Journal</i> , 2021, 14, 100509.	1.6	14
11	Predictive Markers of Bronchial Hyperreactivity in a Large Cohort of Young Adults With Cough Variant Asthma. <i>Frontiers in Pharmacology</i> , 2021, 12, 630334.	1.6	5
12	Detection and characterisation of extracellular vesicles in exhaled breath condensate and sputum of COPD and severe asthma patients. <i>European Respiratory Journal</i> , 2021, 58, 2003024.	3.1	8
13	Medication Adherence in Patients With Severe Asthma Prescribed Oral Corticosteroids in the U-BIOPRED Cohort. <i>Chest</i> , 2021, 160, 53-64.	0.4	10
14	Severe asthma: One disease and multiple definitions. <i>World Allergy Organization Journal</i> , 2021, 14, 100606.	1.6	18
15	Exhaled volatile organic compounds as markers for medication use in asthma. <i>European Respiratory Journal</i> , 2020, 55, 1900544.	3.1	27
16	NMR-Based Metabolomics for the Assessment of Inhaled Pharmacotherapy in Chronic Obstructive Pulmonary Disease Patients. <i>Journal of Proteome Research</i> , 2020, 19, 64-74.	1.8	14
17	Asthma similarities across ProAR (Brazil) and U-BIOPRED (Europe) adult cohorts of contrasting locations, ethnicity and socioeconomic status. <i>Respiratory Medicine</i> , 2020, 161, 105817.	1.3	13
18	Oral Corticosteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI). <i>World Allergy Organization Journal</i> , 2020, 13, 100464.	1.6	30

#	ARTICLE	IF	CITATIONS
19	SIRM-SIAAIC consensus, an Italian document on management of patients at risk of hypersensitivity reactions to contrast media. <i>Clinical and Molecular Allergy</i> , 2020, 18, 13.	0.8	7
20	eNose breath prints as a surrogate biomarker for classifying patients with asthma by atopy. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1045-1055.	1.5	22
21	Development of a Sensing Array for Human Breath Analysis Based on SWCNT Layers Functionalized with Semiconductor Organic Molecules. <i>Advanced Healthcare Materials</i> , 2020, 9, e2000377.	3.9	44
22	Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 577-590.	1.5	140
23	Stratification of asthma phenotypes by airway proteomic signatures. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 70-82.	1.5	59
24	IL-17 <sup>high</sup> asthma with features of a psoriasis immunophenotype. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1198-1213.	1.5	80
25	Epithelial dysregulation in obese severe asthmatics with gastro-oesophageal reflux. <i>European Respiratory Journal</i> , 2019, 53, 1900453.	3.1	15
26	Sputum proteomic signature of gastro-oesophageal reflux in patients with severe asthma. <i>Respiratory Medicine</i> , 2019, 150, 66-73.	1.3	19
27	Identification and prospective stability of electronic nose (eNose)-derived inflammatory phenotypes in patients with severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1811-1820.e7.	1.5	74
28	Treatable traits in the European U-BIOPRED adult asthma cohorts. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 406-411.	2.7	37
29	Methodological considerations for large-scale breath analysis studies: lessons from the U-BIOPRED severe asthma project. <i>Journal of Breath Research</i> , 2019, 13, 016001.	1.5	20
30	Impulse oscillometry and nitrogen washout test in the assessment of small airway dysfunction in asthma: Correlation with quantitative computed tomography. <i>Journal of Asthma</i> , 2019, 56, 323-331.	0.9	9
31	Subtypes of eosinophilic asthma with discrete gene pathway phenotypes. , 2019, , .		0
32	A NMR-based metabolomics approach to the assessment of inhaled pharmacotherapy in patients with COPD. , 2019, , .		0
33	The discovery and development of aclidinium bromide for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 563-577.	2.5	2
34	Sputum proteomics and airway cell transcripts of current and ex-smokers with severe asthma in U-BIOPRED: an exploratory analysis. <i>European Respiratory Journal</i> , 2018, 51, 1702173.	3.1	67
35	Comparison of two exhaled biomarkers in children with and without sleep disordered breathing. <i>Sleep Medicine</i> , 2018, 45, 83-88.	0.8	6
36	Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661876077.	1.0	12

#	ARTICLE	IF	CITATIONS
37	Lipid phenotyping of lung epithelial lining fluid in healthy human volunteers. <i>Metabolomics</i> , 2018, 14, 123.	1.4	17
38	Enhanced oxidative stress in smoking and ex-smoking severe asthma in the U-BIOPRED cohort. <i>PLoS ONE</i> , 2018, 13, e0203874.	1.1	18
39	Breathomics for Assessing the Effects of Treatment and Withdrawal With Inhaled Beclomethasone/Formoterol in Patients With COPD. <i>Frontiers in Pharmacology</i> , 2018, 9, 258.	1.6	25
40	Metabolomic Analysis by Nuclear Magnetic Resonance Spectroscopy as a New Approach to Understanding Inflammation and Monitoring of Pharmacological Therapy in Children and Young Adults With Cystic Fibrosis. <i>Frontiers in Pharmacology</i> , 2018, 9, 595.	1.6	14
41	Large-Scale Label-Free Quantitative Mapping of the Sputum Proteome. <i>Journal of Proteome Research</i> , 2018, 17, 2072-2091.	1.8	16
42	U-BIOPRED accessible handprint: combining omics platforms to identify stable asthma subphenotypes. , 2018, , .		2
43	Measures of adherence in patients with severe asthma prescribed systemic steroids in the U-BIOPRED cohort. , 2018, , .		1
44	Topological data analysis (TDA) of U-BIOPRED paediatric peripheral blood gene expression identified asthma phenotypes characterised by alternative splicing of glucocorticoid receptor (GR) mRNA. , 2018, , .		2
45	Association between exhaled volatile organic compounds and urinary levels of oral corticosteroids within the U-BIOPRED Cohort. , 2018, , .		0
46	Investigational beta-2 adrenergic agonists for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 319-329.	1.9	2
47	Dupilumab for the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 357-366.	1.9	47
48	A European Respiratory Society technical standard: exhaled biomarkers in lung disease. <i>European Respiratory Journal</i> , 2017, 49, 1600965.	3.1	432
49	The potential role of endothelial dysfunction and platelet activation in the development of thrombotic risk in COPD patients. <i>Expert Review of Hematology</i> , 2017, 10, 821-832.	1.0	19
50	U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1797-1807.	1.5	236
51	Volatile Organic Compounds Breathprinting of U-BIOPRED Severe Asthma smokers/ex-smokers cohort. , 2017, , .		2
52	Late Breaking Abstract - Cluster analysis of treatable traits in the U-BIOPRED adult severe asthma cohort. , 2017, , .		0
53	Urinary metabolomics-based molecular sub-phenotyping of the U-BIOPRED asthma cohort. , 2017, , .		0
54	NMR-based metabolomics of exhaled breath condensate for assessing the effects of inhaled corticosteroids in COPD patients. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
55	Investigational prostaglandin D2receptor antagonists for airway inflammation. Expert Opinion on Investigational Drugs, 2016, 25, 639-652.	1.9	21
56	Triple inhaled therapy for chronic obstructive pulmonary disease. Drug Discovery Today, 2016, 21, 1820-1827.	3.2	30
57	Vilanterol trifenate for the treatment of COPD. Expert Review of Respiratory Medicine, 2016, 10, 719-731.	1.0	12
58	Exhaled and non-exhaled non-invasive markers for assessment of respiratory inflammation in patients with stable COPD and healthy smokers. Journal of Breath Research, 2016, 10, 017102.	1.5	48
59	Electronic Nose and Exhaled Breath NMR-based Metabolomics Applications in Airways Disease. Current Topics in Medicinal Chemistry, 2016, 16, 1610-1630.	1.0	65
60	Effects of treatment and withdrawal with inhaled beclomethasone/formoterol on electronic nose and NMR metabolomic breathprints in patients with COPD. , 2016, , .		0
61	Comparison of classification methods in breath analysis by electronic nose. Journal of Breath Research, 2015, 9, 046002.	1.5	68
62	Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends. Journal of Medicinal Chemistry, 2015, 58, 4131-4164.	2.9	76
63	Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. European Respiratory Journal, 2015, 46, 1308-1321.	3.1	434
64	Role of beta-blockers in patients with COPD: current perspective. Drug Discovery Today, 2015, 20, 129-135.	3.2	18
65	Characteristics of the frequent exacerbator in U-BIOPRED adult severe asthma cohort. , 2015, , .		3
66	The Combined Impact of Exhaled Nitric Oxide and Sputum Eosinophils Monitoring in Asthma Treatment: A Prospective Cohort Study. Current Pharmaceutical Design, 2015, 21, 4752-4762.	0.9	18
67	The first U-BIOPRED sputum handprint of severe asthma. , 2015, , .		0
68	The first U-BIOPRED blood handprint of severe asthma. , 2015, , .		0
69	Breathomics can discriminate between anti IgE-treated and non-treated severe asthma adults. , 2015, , .		0
70	Unbiased clustering of severe asthma patients based on exhaled breath profiles. , 2015, , .		0
71	Exhaled breath VOCs are associated with nocturnal waking in asthmatic children. , 2015, , .		0
72	Computed tomography for evaluation of the small airway disease in asthma. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
73	Nuclear Magnetic Resonance <sup>1</sup> -based Metabolomics Discriminates Primary Ciliary Dyskinesia from Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 229-233.	2.5	46
74	An investigation on e-nose platform relevance to respiratory diseases. , 2014, , .		1
75	High sputum total adiponectin is associated with low odds for asthma. <i>Journal of Asthma</i> , 2014, 51, 459-466.	0.9	13
76	Exhaled Nitric Oxide as a Biomarker in COPD and Related Comorbidities. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	78
77	Liquid chromatography <sup>2</sup> -mass spectrometry measurement of leukotrienes in asthma and other respiratory diseases. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 964, 12-25.	1.2	34
78	Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. <i>Drug Discovery Today</i> , 2014, 19, 1928-1935.	3.2	53
79	Transcriptional regulation of kinases downstream of the T cell receptor: another immunomodulatory mechanism of glucocorticoids. <i>BMC Pharmacology &amp; Toxicology</i> , 2014, 15, 35.	1.0	23
80	Within-day and between-day repeatability of measurements with an electronic nose in patients with COPD. <i>Journal of Breath Research</i> , 2013, 7, 017103.	1.5	75
81	The Electronic Nose in Respiratory Medicine. <i>Respiration</i> , 2013, 85, 72-84.	1.2	151
82	Separating Smoking-Related Diseases Using NMR-Based Metabolomics of Exhaled Breath Condensate. <i>Journal of Proteome Research</i> , 2013, 12, 1502-1511.	1.8	98
83	Application of <sup>3</sup> omics technologies to biomarker discovery in inflammatory lung diseases. <i>European Respiratory Journal</i> , 2013, 42, 802-825.	3.1	234
84	Measurement of Biomarkers of Oxidative Stress and Airway Inflammation in Exhaled Breath Condensate: Methodology and Potential Applications in Patients with COPD and Healthy Smokers. , 2013, , 360-381.		3
85	Long-Acting Beta-Agonists and their Association with Inhaled Corticosteroids in COPD. <i>Current Medicinal Chemistry</i> , 2013, 20, 1477-1495.	1.2	54
86	Editorial (Hot Topic: Drugs for Chronic Obstructive Pulmonary Disease). <i>Current Medicinal Chemistry</i> , 2013, 20, 1461-1463.	1.2	8
87	Inhaled Muscarinic Acetylcholine Receptor Antagonists for Treatment of COPD. <i>Current Medicinal Chemistry</i> , 2013, 20, 1464-1476.	1.2	41
88	Exhaled Nitric Oxide Measurement in Patients Affected by Nasal Polyposis. <i>Otolaryngology - Head and Neck Surgery</i> , 2012, 147, 351-356.	1.1	20
89	NMR spectroscopy metabolomic profiling of exhaled breath condensate in patients with stable and unstable cystic fibrosis. <i>Thorax</i> , 2012, 67, 222-228.	2.7	157
90	Pharmacotherapy of Patients with Mild Persistent Asthma: Strategies and Unresolved Issues. <i>Frontiers in Pharmacology</i> , 2011, 2, 35.	1.6	17

#	ARTICLE	IF	CITATIONS
91	New perspectives in pharmacological treatment of mild persistent asthma. <i>Drug Discovery Today</i> , 2011, 16, 1084-1091.	3.2	59
92	Exhaled Breath Condensate Biomarkers of Airway Inflammation and Oxidative Stress in COPD. , 2011, , 421-440.		0
93	Diagnostic Performance of an Electronic Nose, Fractional Exhaled Nitric Oxide, and Lung Function Testing in Asthma. <i>Chest</i> , 2010, 137, 790-796.	0.4	191
94	Toward a Personalized Pharmacotherapy of Respiratory Diseases. <i>Frontiers in Pharmacology</i> , 2010, 1, 131.	1.6	13
95	Role of Leukotrienes and Leukotriene Modifiers in Asthma. <i>Pharmaceuticals</i> , 2010, 3, 1792-1811.	1.7	42
96	Measurement of 8-Isoprostane in Exhaled Breath Condensate. <i>Methods in Molecular Biology</i> , 2010, 594, 73-84.	0.4	30
97	8-Isoprostane in Exhaled Breath Condensate and Exercise-Induced Bronchoconstriction in Asthmatic Children and Adolescents. <i>Chest</i> , 2009, 135, 66-73.	0.4	97
98	Pharmacotherapy of asthma: regular treatment or on demand?. <i>Therapeutic Advances in Respiratory Disease</i> , 2009, 3, 175-191.	1.0	5
99	LC/MS/MS analysis of leukotriene B4 and other eicosanoids in exhaled breath condensate for assessing lung inflammation. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 1272-1280.	1.2	87
100	Acute Effects of Air Pollution on Pulmonary Function, Airway Inflammation, and Oxidative Stress in Asthmatic Children. <i>Environmental Health Perspectives</i> , 2009, 117, 668-674.	2.8	208
101	Acute Effects of Air Pollution on Pulmonary Function, Airway Inflammation, and Oxidative Stress in Asthmatic Children. <i>Environmental Health Perspectives</i> , 2009, 117, 668-674.	2.8	170
102	Exhaled 8-isoprostane and prostaglandin E2 in patients with stable and unstable cystic fibrosis. This work was performed at the Catholic University of the Sacred Heart, Rome, Italy, and Ospedale Pediatrico Bambino Gesù, Rome, Italy. This work was funded by the Catholic University of the Sacred Heart. <i>Free Radical Biology and Medicine</i> , 2008, 45, 913-919.	1.3	79
103	Chronic Obstructive Pulmonary Disease Phenotyping: A Possible Role for 8-Isoprostane Measurement in Exhaled Breath Condensate?. <i>Respiration</i> , 2008, 75, 134-135.	1.2	4
104	Leukotrienes, Antileukotrienes and Asthma. <i>Mini-Reviews in Medicinal Chemistry</i> , 2008, 8, 647-656.	1.1	66
105	Insights into Oxidative Stress: The Isoprostanes. <i>Current Medicinal Chemistry</i> , 2007, 14, 703-717.	1.2	222
106	Effects of Montelukast Treatment and Withdrawal on Fractional Exhaled Nitric Oxide and Lung Function in Children With Asthma. <i>Chest</i> , 2007, 132, 1876-1881.	0.4	69
107	Review: Analysis of exhaled breath condensate in respiratory medicine: methodological aspects and potential clinical applications. <i>Therapeutic Advances in Respiratory Disease</i> , 2007, 1, 5-23.	1.0	151
108	Pharmacological modulation of the leukotriene pathway in allergic airway disease. <i>Drug Discovery Today</i> , 2007, 12, 404-412.	3.2	76

#	ARTICLE	IF	CITATIONS
109	Effects of a leukotriene receptor antagonist on exhaled leukotriene E4 and prostanoids in children with asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 118, 347-353.	1.5	94
110	Isoprostanes and asthma. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2006, 3, 287-292.	0.5	8
111	Pharmacological treatment of chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2006, 1, 409-423.	0.9	36
112	Inflammatory Response to Sputum Induction Measured by Exhaled Markers. <i>Respiration</i> , 2005, 72, 594-599.	1.2	19
113	Exhaled breath condensate analysis in patients with COPD. <i>Clinica Chimica Acta</i> , 2005, 356, 22-34.	0.5	86
114	Liquid chromatography/mass spectrometry analysis of exhaled leukotriene B4 in asthmatic children. <i>Respiratory Research</i> , 2005, 6, 119.	1.4	63
115	Ion trap liquid chromatography/tandem mass spectrometry analysis of leukotriene B4 in exhaled breath condensate. <i>Rapid Communications in Mass Spectrometry</i> , 2004, 18, 2723-2729.	0.7	60
116	Effects of inhaled corticosteroids on exhaled leukotrienes and prostanoids in asthmatic children. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 761-767.	1.5	121
117	Isoprostanes: markers and mediators of oxidative stress. <i>FASEB Journal</i> , 2004, 18, 1791-1800.	0.2	642
118	Increased Exhaled 8-Isoprostane in Childhood Asthma. <i>Chest</i> , 2003, 124, 25-31.	0.4	134
119	Increased Exhaled Cysteinyl-Leukotrienes and 8-Isoprostane in Aspirin-induced Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 166, 301-306.	2.5	186
120	Diagnosing Nonimmediate Reactions to Penicillins by in vivo Tests. <i>International Archives of Allergy and Immunology</i> , 2002, 129, 169-174.	0.9	111
121	Exhaled leukotrienes and prostaglandins in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 615-620.	1.5	210
122	Analysis of exhaled breath condensate for monitoring airway inflammation. <i>Trends in Pharmacological Sciences</i> , 2002, 23, 232-237.	4.0	171
123	Ozone-induced increase in exhaled 8-isoprostane in healthy subjects is resistant to inhaled budesonide. <i>Free Radical Biology and Medicine</i> , 2002, 33, 1403-1408.	1.3	58
124	Indirect monitoring of lung inflammation. <i>Nature Reviews Drug Discovery</i> , 2002, 1, 238-242.	21.5	77
125	Exhaled Carbon Monoxide and Nitric Oxide in COPD. <i>Chest</i> , 2001, 120, 496-501.	0.4	149
126	Increased Nitrosothiols in Exhaled Breath Condensate in Inflammatory Airway Diseases. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 163, 854-858.	2.5	191

#	ARTICLE	IF	CITATIONS
127	Exhaled 8-Isoprostane as an <i>In Vivo</i> Biomarker of Lung Oxidative Stress in Patients with COPD and Healthy Smokers. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, 1175-1177.	2.5	514
128	Increased 8-Isoprostane, a Marker of Oxidative Stress, in Exhaled Condensate of Asthma Patients. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999, 160, 216-220.	2.5	491
129	Anaphylaxis increases 8-iso-prostaglandin F <sub>2</sub> ± release from guinea-pig lung in vitro. <i>European Journal of Pharmacology</i> , 1999, 365, 59-64.	1.7	56
130	8-Isoprostane as a Biomarker of Oxidative Stress in Interstitial Lung Diseases. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998, 158, 1524-1527.	2.5	236
131	Tachykinin NK2 receptor antagonists decrease eicosanoid release in lung anaphylaxis. <i>European Journal of Pharmacology</i> , 1996, 313, R1-R3.	1.7	4
132	In vitro testing for lung toxicity: a method for distinguishing between immune- and non-immune-mediated reactions to xenobiotics. <i>Environmental Toxicology and Pharmacology</i> , 1996, 2, 201-205.	2.0	1
133	Gallbladder emptying, plasma levels of estradiol and progesterone, and cholecystokinin secretion in liver cirrhosis. <i>Digestive Diseases and Sciences</i> , 1995, 40, 428-434.	1.1	25
134	Blood levels of vasoactive intestinal polypeptide in normal and growth retarded fetuses: relationship with acid-base and haemodynamic status. <i>Early Human Development</i> , 1995, 41, 69-77.	0.8	7
135	Interleukin-1 receptor antagonist displays intrinsic agonist activity on rat gastric fundus motility in vitro. <i>European Journal of Pharmacology</i> , 1995, 275, 31-37.	1.7	3
136	Corrigendum to "Interleukin-1 receptor antagonist displays intrinsic agonist activity on rat gastric fundus motility in vitro" [Eur. J. Pharmacol. 275 (1995) 31-37]. <i>European Journal of Pharmacology</i> , 1995, 282, 263.	1.7	0
137	Evidence that interleukin-1 <sup>±</sup> and tumor necrosis factor inhibit gastric fundus motility via the 5-lipoxygenase pathway. <i>European Journal of Pharmacology</i> , 1994, 252, 253-260.	1.7	21
138	Interleukin-1 <sup>±</sup> and tumour necrosis factor inhibit rat gastric fundus motility in vitro. <i>European Journal of Pharmacology</i> , 1993, 233, 303-304.	1.7	16
139	Effects of vasoactive intestinal polypeptide on antigen-induced bronchoconstriction and thromboxane release in guinea-pig lung. <i>British Journal of Pharmacology</i> , 1993, 109, 243-250.	2.7	15